Cancer Family
Malignant Nervous System Neoplasm
CI-CAN-00000246Explore in graph →
953 active trials7 approved drugs131 evidence items
- NCIt
- C4788
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000246Explore in graph →
Clinical trials
3,457 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (495)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03927222 | Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma(I-ATTAC) | terminated | Phase 2 | 6 | Mustafa Khasraw, MBChB, MD, FRCP, FRACPOTHER | 1 | Apr 8, 2024 | clinicaltrials |
| NCT03275402 | 131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases | terminated | Phase 2 / Phase 3 | 52 | Y-mAbs TherapeuticsINDUSTRY | 4 | Feb 13, 2024 |
| clinicaltrials |
| NCT02768337 | Cambridge Brain Mets Trial 1(CamBMT1) | terminated | Phase 1 / Phase 2 | 26 | Cambridge University Hospitals NHS Foundation TrustOTHER | 1 | Jan 31, 2024 | clinicaltrials |
| NCT03458728 | Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients | terminated | Phase 1 / Phase 2 | 31 | BayerINDUSTRY | 1 | Dec 4, 2023 | clinicaltrials |
| NCT03190967 | T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery | terminated | Phase 1 / Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Oct 11, 2023 | clinicaltrials |
| NCT04167618 | 177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma | terminated | Phase 1 / Phase 2 | 2 | Y-mAbs TherapeuticsINDUSTRY | 5 | Oct 6, 2023 | clinicaltrials |
| NCT03860207 | Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers | terminated | Phase 1 / Phase 2 | 12 | Y-mAbs TherapeuticsINDUSTRY | 1 | Sep 13, 2023 | clinicaltrials |
| NCT00788125 | Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors | terminated | Phase 1 / Phase 2 | 7 | City of Hope Medical CenterOTHER | 1 | Jul 14, 2023 | clinicaltrials |
| NCT01721577 | Phase I/II Trial of AXL1717 in the Treatment of Recurrent Malignant Astrocytomas(AXL1717) | terminated | Phase 1 / Phase 2 | 10 | Rush University Medical CenterOTHER | 1 | May 22, 2023 | clinicaltrials |
| NCT04730349 | A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer(PIVOT IO 020) | terminated | Phase 1 / Phase 2 | 15 | Bristol-Myers SquibbINDUSTRY | 6 | Mar 24, 2023 | clinicaltrials |
| NCT03430791 | Trial of Combination Tumor Treating Fields (TTF; Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent Glioblastoma | terminated | Phase 2 | 5 | Baptist Health South FloridaOTHER | 1 | Feb 2, 2023 | clinicaltrials |
| NCT01986348 | Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent Gliomas(KING) | terminated | Phase 2 | 76 | Karyopharm Therapeutics IncINDUSTRY | 3 | Jan 26, 2023 | clinicaltrials |
| NCT01822275 | Phase II Trial of Low-Dose Whole Brain Radiotherapy With Concurrent Temozolomide and Adjuvant Temozolomide in Patients With Newly-Diagnosed Glioblastoma Multiforme(GCC 1224) | terminated | Phase 2 | 24 | University of Maryland, BaltimoreOTHER | 1 | Dec 29, 2022 | clinicaltrials |
| NCT03119064 | BrUOG 329 Onivyde & Metronomic Temozolomide in Recurrent Glioblastoma(329) | terminated | Phase 1 / Phase 2 | 12 | Brown UniversityOTHER | 1 | Dec 13, 2022 | clinicaltrials |
| NCT02641782 | NB2013-HR German (GPOH) / Dutch (DCOG) Trial(NB2013-HR) | terminated | Phase 2 | 3 | University of CologneOTHER | 1 | Nov 4, 2022 | clinicaltrials |
| NCT02885324 | Pilot Study of Cabozantinib for Recurrent or Progressive Central Nervous System Tumors in Children | terminated | Phase 2 | 4 | Indiana UniversityOTHER | 1 | Oct 6, 2022 | clinicaltrials |
| NCT02601209 | Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma | terminated | Phase 1 / Phase 2 | 151 | National Cancer Institute (NCI)NIH | 1 | Aug 23, 2022 | clinicaltrials |
| NCT03856099 | TTAC-0001 Phase II Trial With Recurrent Glioblastoma Progressed on Bevacizumab | terminated | Phase 2 | 19 | PharmAbcineINDUSTRY | 2 | Aug 18, 2022 | clinicaltrials |
| NCT03022578 | Laser Interstitial Thermal Therapy and Lomustine in Treating Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma | terminated | Phase 2 | 7 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2022 | clinicaltrials |
| NCT01884740 | Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22 | terminated | Phase 1 / Phase 2 | 13 | Weill Medical College of Cornell UniversityOTHER | 1 | Aug 9, 2022 | clinicaltrials |
| NCT03727841 | Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord Ependymoma | terminated | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 1 | Jul 27, 2022 | clinicaltrials |
| NCT02663271 | TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma | terminated | Phase 2 | 10 | University of FloridaOTHER | 1 | Jun 23, 2022 | clinicaltrials |
| NCT00479765 | A Phase 1 / 2 Dose Escalation Study of Locally-Administered OncoGel™ in Subjects With Recurrent Glioma | terminated | Phase 1 / Phase 2 | 4 | Boston Scientific CorporationINDUSTRY | 1 | Jun 22, 2022 | clinicaltrials |
| NCT00669669 | O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas | terminated | Phase 1 / Phase 2 | 12 | Fred Hutchinson Cancer CenterOTHER | 1 | May 18, 2022 | clinicaltrials |
| NCT03641326 | Sunitinib in Sarcomas of the Central Nervous System | terminated | Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | Apr 19, 2022 | clinicaltrials |
| NCT02420795 | Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | terminated | Phase 1 / Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 4, 2022 | clinicaltrials |
| NCT01587144 | Safety and Efficacy Study of Lucanthone When Used in Combination With Temozolomide(TMZ) and Radiation to Treat Glioblastoma Multiforme(GBM) | terminated | Phase 2 | 18 | Spectrum Pharmaceuticals, IncINDUSTRY | 2 | Oct 19, 2021 | clinicaltrials |
| NCT03906448 | FORWARD Optune and Adjuvant TMZ in Grade II/III Astrocytoma(FORWARD) | terminated | Phase 2 | 1 | University of FloridaOTHER | 1 | Sep 23, 2021 | clinicaltrials |
| NCT01110876 | Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM) | terminated | Phase 1 / Phase 2 | 21 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 25, 2021 | clinicaltrials |
| NCT02691026 | A Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor (MPNST), Not Eligible for Curative Surgery | terminated | Phase 2 | 8 | Oslo University HospitalOTHER | 1 | Jun 23, 2021 | clinicaltrials |
| NCT02046187 | Ketogenic Diet With Radiation and Chemotherapy for Newly Diagnosed Glioblastoma | terminated | Phase 1 / Phase 2 | 14 | St. Joseph's Hospital and Medical Center, PhoenixOTHER | 1 | Jun 16, 2021 | clinicaltrials |
| NCT02743078 | Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma | terminated | Phase 2 | 3 | RTOG Foundation, Inc.OTHER | 1 | Jun 2, 2021 | clinicaltrials |
| NCT02340156 | Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma | terminated | Phase 2 | 1 | SynerGene Therapeutics, Inc.INDUSTRY | 2 | Mar 3, 2021 | clinicaltrials |
| NCT02758366 | Prolonged Exposure to Doxorubicin in Patients With Glioblastoma Multiforme and Diffuse Intrinsic Pontine Glioma | terminated | Phase 2 | 21 | Meyer Children's Hospital IRCCSOTHER | 1 | Feb 9, 2021 | clinicaltrials |
| NCT02296476 | A Dose-finding Study of Birabresib (MK-8628) in Participants With Recurrent Glioblastoma Multiforme (MK-8628-002) | terminated | Phase 2 | 12 | Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 0 | Jan 26, 2021 | clinicaltrials |
| NCT00202930 | Use of Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma | terminated | Phase 2 | 4 | Jean M. Tersak, M.D.OTHER | 0 | Jan 22, 2021 | clinicaltrials |
| NCT02607124 | A Phase I/II Study of Ribociclib,a CDK4/6 Inhibitor, Following Radiation Therapy | terminated | Phase 1 / Phase 2 | 11 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Nov 5, 2020 | clinicaltrials |
| NCT02709889 | Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 200 | AbbVieINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT00698009 | Haploidentical Natural Killer (NK) Cells in Patients With Relapsed or Refractory Neuroblastoma | terminated | Phase 2 | 1 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 24, 2020 | clinicaltrials |
| NCT01973062 | Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Primary Central Nervous System Non-Hodgkin Lymphoma | terminated | Phase 2 | 1 | Case Comprehensive Cancer CenterOTHER | 1 | Jul 24, 2020 | clinicaltrials |
| NCT02855086 | Cetuximab-IRDye 800CW in Detecting Tumors in Patients With Malignant Glioma Undergoing Surgery | terminated | Phase 1 / Phase 2 | 3 | Eben RosenthalOTHER | 1 | Mar 31, 2020 | clinicaltrials |
| NCT01478321 | Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas | terminated | Phase 2 | 54 | Northwestern UniversityOTHER | 1 | Mar 12, 2020 | clinicaltrials |
| NCT01349036 | A Phase 2 Study of PLX3397 in Patients With Recurrent Glioblastoma | terminated | Phase 2 | 38 | Daiichi SankyoINDUSTRY | 1 | Mar 3, 2020 | clinicaltrials |
| NCT01392352 | HYPAZ: Hypertension Induced by Pazopanib(HYPAZ) | terminated | Phase 2 | 31 | Cambridge University Hospitals NHS Foundation TrustOTHER | 1 | Feb 13, 2020 | clinicaltrials |
| NCT02414165 | The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma(Toca5) | terminated | Phase 2 / Phase 3 | 403 | Tocagen Inc.INDUSTRY | 4 | Feb 7, 2020 | clinicaltrials |
| NCT02684071 | Phase II Study of Intraventricular Methotrexate in Children With Recurrent or Progressive Malignant Brain Tumors | terminated | Phase 2 | 3 | Nicklaus Children's Hospital f/k/a Miami Children's HospitalOTHER | 1 | Jan 10, 2020 | clinicaltrials |
| NCT02465528 | Ceritinib Rare Indications Study in ALK+ Tumors | terminated | Phase 2 | 22 | Novartis PharmaceuticalsINDUSTRY | 8 | Dec 27, 2019 | clinicaltrials |
| NCT01183884 | 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater Remission of High-Risk Neuroblastoma | terminated | Phase 2 | 46 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 14, 2019 | clinicaltrials |
| NCT02177773 | GA-68 DOTA-TOC of Somatostatin Positive Malignancies(DOTA-TOC) | terminated | Phase 1 / Phase 2 | 300 | University of California, San FranciscoOTHER | 1 | Nov 12, 2019 | clinicaltrials |
| NCT01182350 | Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG) | terminated | Phase 2 | 53 | Karen D. Wright MDOTHER | 1 | Sep 4, 2019 | clinicaltrials |
Data updated 22 days agoSource updated Apr 8, 2024source: clinicaltrials